AMNEAL PHARMACEUTICALS, INC. (AMRX): what the price requires

At today's price, AMNEAL PHARMACEUTICALS, INC. (AMRX) is priced for +7.9% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-19 · Source: https://boothcheck.com/report/AMRX

Headline

FieldValue
TickerAMRX
CompanyAMNEAL PHARMACEUTICALS, INC.
Current price$17.21/sh

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin needed3.3%
Operating margin today14.5%
Margin compression implied-11.2pp
Implied growth7.9%
Multiple paid19x operating income

The operating-margin requirement is derived from the framework's value band at year 11, a separately labeled basis from the headline growth/duration solve.

Solve inputs: computed at a 8.3% cost of capital with 4% terminal growth over a 5-year stage; each 1pp of cost of capital moves the implied operating-profit growth ~6.9pp.

How unusual the bet is: within-range

ReferenceValue
vs own history+0.35σ
cohort percentile (of 113 peers)36
implied end-window share0%

Valuation X-Ray

Every valuation family lands below the price. The price therefore requires assumptions beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset—0—
Earnings1.44x1expensive
Relative1.27x2expensive
Growth—0—

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.9%); the inversion above states its own rate.

Per-Model Detail (n=3)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$15.021.15xnoFCF base $0.3B, growth 8% (input: historical growth), terminal g 4.0%, WACC 7.9%, 6yr projection
DCF Exit MultipleGrowth$18.050.95xnoExit EV/EBITDA: 16.5x / 18.5x / 20.5x (bear / base = today's held flat / bull), 6yr
Relative ValuationRelative$13.111.31xyesP/E 30.71x (blended: static sector reference 24x + trailing (TTM) 46x), scenarios: 25.7x / 30.7x / 35.7x (bear / base = reference held flat / bull), EV/EBITDA 16x
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset——no—
Two-Stage Excess ReturnAsset——no—
Discounted Future Market CapGrowth$14.171.21xnoRev $3.0B, growth 8% (input: historical growth; tapered), Terminal P/S: 1.6x / 1.9x / 2.2x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelative$4.443.88xnoEPS $0.37, growth 2% (input: historical EPS growth), PEG=23.18 (Overvalued)
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings$0.7323.58xnoNormalized EBIT (5y avg op income, one-time charges added back) $0.21B × (1−3%) / WACC 7.9% → EPV (no growth)
Residual IncomeAsset——no—
Graham NumberAsset——no—
EV/EBITDA RelativeRelative$13.951.23xyesEBITDA $0.44B × sector EV/EBITDA 16.0x
FCF YieldEarnings$0.6825.31xyesFCF $240.8M / Kₑ 9.3% — zero-growth perpetuity (excluded from median)
SBC-Adj FCF YieldEarnings$0.011721.00xyesSBC-adj FCF $0.21B (FCF $0.24B − SBC $0.03B) capitalized at Kₑ (excluded from median)
Ben Graham FormulaEarnings$11.941.44xyesEPS $0.37 × (8.5 + 2×15.0%) × (4.4 / 5.3%)
ROIC-Justified P/BAsset——no—
P/Sales SectorRelative$37.040.46xnoRevenue $3.05B × sector P/S 4.0x
PEG Fair ValueRelative$13.881.24xnoEPS $0.37 × (PEG 1.5 × growth 25.0% (input: historical EPS growth)) → PE 37.5x
Earnings YieldEarnings$4.004.30xnoEPS $0.37 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Net debt$2.4b
Net debt / NOPAT (after-tax)5.76x
Net debt / operating income (pre-tax)5.60x
Share count CAGR (dilution)2.3%
Burning cashno

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

Bull Case

The single most decisive metric in this story is the specialty segment's growth, because it is the evidence that Amneal is climbing out of the commodity end of pharma. Specialty grew 23% in the most recent quarter, driven by newer branded products in women's health, ADHD, and Parkinson's disease, with strong uptake of CREXONT and rapid adoption of Brekiya for cluster headaches. That matters because generics is a brutal business: the filing describes competitors who "offer substitutes for branded pharmaceutical products at significantly lower prices" and rivals with "significantly greater financial, R&D, marketing, and other resources than we do." A growing specialty franchise with branded, harder-to-substitute products is how a generics maker escapes that race to the bottom, and the 23% print says the escape is underway.

The overall results show the model converting to profit, not just revenue. The most recent quarter delivered net revenue of $723 million, up 4%, with adjusted EBITDA up 19% and margin expansion, alongside GAAP net income of $62 million. Adjusted EBITDA growing nearly five times faster than revenue is exactly the signature of a mix shift toward higher-margin specialty products, and it is what makes the deleveraging story credible: every incremental EBITDA dollar both improves the margin and chips away at the debt ratio.

The biosimilars pipeline is the multi-year growth vector layered on top. Management has framed biosimilars as a future growth driver projected to contribute $1.0 to $1.3 billion to 2030 revenue, supported by a plan for multiple annual launches. Biosimilars are a structurally attractive adjacency for a company that already knows how to manufacture complex generics at scale: they face fewer competitors than small-molecule generics, carry better economics, and address a growing slice of drug spending as more biologics lose exclusivity. For a company the market is only asking to grow mid-single-digits, a credible billion-dollar biosimilar ramp is upside the price does not fully demand.

Bear Case

Begin with the qualitative reality before the ratio: Amneal built its transformation on borrowed money, and the debt is now the gravity the equity story has to overcome. The company carries net debt near $2.4 billion against trailing operating income of about $435 million, roughly 5.5 times, and the filing's debt schedule shows the structure plainly, including a "Term Loan Due 2028" of more than $2.3 billion that anchors the obligations, with a repricing amendment to the 2032 term loan executed in early 2026. A leveraged specialty pharma is a fine thing while EBITDA is rising; it becomes a problem the moment growth stalls, because the debt does not flex and the interest does not wait. The deleveraging thesis is real, but it is a thesis, not a fact, and it depends on the specialty and biosimilar ramps continuing without interruption.

The price-to-fundamentals picture is consistent with that tension rather than wildly out of line, which is what makes the bear case structural rather than a valuation scream. At about 18 times operating income, the price embeds roughly 6.5% annual operating growth, within what the company has recently delivered. The earnings-power and peer-multiple lenses both read the price as modestly above what the current business supports. So the bear is not that Amneal is grossly overvalued; it is that the price already credits a smooth continuation of the mix shift, leaving little cushion if the specialty launches mature, if a key product faces unexpected competition, or if the biosimilar launches slip.

The competitive backdrop is the variable that can break the growth assumption. Generics remains the larger part of the business, and the filing is candid that competitors may "develop products and/or processes competitive with, or superior to, ours," while Amneal may not always "successfully develop or introduce new products, on a timely basis or at all." Specialty and biosimilars are harder to commoditize, but they are also harder and more expensive to develop, and they attract better-resourced rivals. The bear thesis is that a debt-laden company executing a difficult, multi-year transition, against larger competitors and with limited margin for error, is priced for the transition to go right at every step.

Valuation

At the current price the market pays about 18 times company-wide operating income, which inverts to roughly 6.5% operating growth a year for five years. Against Amneal's own recent record that pace is within reach; the demand is in its persistence through a transition from generics toward specialty and biosimilars, not in an unusually high rate. The price is asking the mix shift to keep working, which is a reasonable bet given the recent prints, but it is a bet on execution continuing rather than on a low hurdle.

The methods we use to triangulate are thin here, and what they show points the same way. The earnings-power lens reads the price modestly above what current operating earnings support, and the peer-multiple lens, comparing Amneal to other drug manufacturers, reaches a similar conclusion. There is no deep asset floor and no growth-method windfall in the picture; the price is justified chiefly on where comparable companies trade. That makes this a relative-value name whose support rests on the peer multiple holding and the EBITDA trajectory continuing, rather than on an asset or earnings cushion beneath the current level.

Solvency is the load-bearing constraint and belongs in the close. Net debt near $2.4 billion, about 5.5 times operating income, is the number that governs the equity, because at that leverage the path of EBITDA decides everything: rising EBITDA deleverages the company and lifts the equity, while a stall does the reverse with force. The share count has crept up around 2% a year, a mild dilution rather than aggressive issuance, so the capital structure is being managed through earnings growth rather than equity raises. The decisive fact is not the modest growth the price requires; it is that a 5.5-times-levered company has to keep its specialty and biosimilar engines running to make the debt shrink instead of bite, and the valuation already assumes it will.

Catalysts

The first-quarter 2026 print was a clean beat that supported the raised outlook. Amneal reported net revenue of $723 million with GAAP net income of $62 million and diluted EPS of $0.19, while adjusted EBITDA rose 19% to $202 million, with revenue up 4%, margin expansion, and specialty-product momentum. For discipline, the $0.27 adjusted EPS the company highlights is a non-GAAP measure; the GAAP figures are the ones this report is built on. Management affirmed full-year 2026 guidance of $3.05 to $3.15 billion in net revenue, $740 to $770 million in adjusted EBITDA, and $350 to $400 million in operating cash flow.

The forward catalysts are the biosimilar launches and the deleveraging they fund. Management detailed multi-year targets with biosimilars projected to contribute $1.0 to $1.3 billion to 2030 revenue and plans for multiple annual launches, the growth vector the price increasingly leans on. On the sell side, UBS initiated coverage with a Buy and a $19 target, while others sit closer to $16 to $17, a spread that reflects differing confidence in how fast biosimilars and specialty scale. The watch list is the cadence of biosimilar approvals and launches, continued specialty growth from CREXONT and Brekiya, and the leverage ratio falling as adjusted EBITDA climbs.

Peer Cohorts (Per Segment, With Filing Citations)

F-67 (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Amneal Q1 2026 results, May 2026 · Amneal 10-K and subsequent events · analyst notes, 2026

View the full interactive AMRX report on boothcheck